Accès gratuit
Numéro |
Med Sci (Paris)
Volume 27, Numéro 8-9, Août–Septembre 2011
|
|
---|---|---|
Page(s) | 725 - 732 | |
Section | M/S Revues | |
DOI | https://doi.org/10.1051/medsci/2011278014 | |
Publié en ligne | 31 août 2011 |
- Ray-Gallet D, Gérard A, Polo S, Almouzni G. Variations sur le thème du « code histone ». Med Sci (Paris) 2005 ; 21 : 384-389. [Google Scholar]
- Kouzarides T. Chromatin modifications and their function. Cell 2007 ; 128 : 693-705. [CrossRef] [PubMed] [Google Scholar]
- Mottet D, Castronovo V. Les histone désacétylases. Nouvelles cibles pour les thérapies anti-cancéreuses. Med Sci (Paris) 2008 ; 24 : 742-6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Sowa Y. Development of HDAC inhibitors. Gan To Kagaku Ryoho 2010 ; 37 : 1665-1668. [PubMed] [Google Scholar]
- Albert M, Helin K. Histone methyltransferases in cancer. Sem Cell Dev Biol 2010 ; 21 : 209-220. [CrossRef] [Google Scholar]
- Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002 ; 12 : 198-209. [CrossRef] [PubMed] [Google Scholar]
- Schneider R, Bannister AJ, Kouzarides T. Unsafe SET: histone lysine methyltransferases and cancer. Trends Biochem Sci 2002 ; 27 : 396-402. [CrossRef] [PubMed] [Google Scholar]
- Peters AH, O’Carroll D, Scherthan H, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001 ; 107 : 323-337. [CrossRef] [PubMed] [Google Scholar]
- Czvitkovich S, Sauer S, Peters AH, et al. Over-expression of the SUV39H1 histone methyltransferase induces altered proliferation and differentiation in transgenic mice. Mech Dev 2001 ; 107 : 141-153. [CrossRef] [PubMed] [Google Scholar]
- Nielsen SJ, Schneider R, Bauer UM, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001 ; 412 : 561-565. [CrossRef] [PubMed] [Google Scholar]
- Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2001 ; 8 : 1487-1503. [PubMed] [Google Scholar]
- Cattaneo F, Nucifora G. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Biochem 2008 ; 105 : 344-352. [CrossRef] [PubMed] [Google Scholar]
- Carbone R, Botrugno OA, Ronzoni S, et al. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 2006 ; 26 : 1288-1296. [CrossRef] [PubMed] [Google Scholar]
- Goyama S, Nitta E, Yoshino T, et al. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia 2010 ; 24 : 81-88. [CrossRef] [PubMed] [Google Scholar]
- Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007 ; 7 : 823-833. [CrossRef] [PubMed] [Google Scholar]
- Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001 ; 20 : 5695-5707. [CrossRef] [PubMed] [Google Scholar]
- Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003 ; 17 : 2298-2307. [CrossRef] [PubMed] [Google Scholar]
- Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005 ; 121 : 167-178. [CrossRef] [PubMed] [Google Scholar]
- Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007 ; 21 : 525-530. [CrossRef] [PubMed] [Google Scholar]
- Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002 ; 419 : 624-629. [CrossRef] [PubMed] [Google Scholar]
- Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell 2005 ; 18 : 263-272. [Google Scholar]
- Cheung N, Chan LC, Thompson A, et al. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 2007 ; 9 : 1208-1215. [CrossRef] [PubMed] [Google Scholar]
- Majumder S, Liu Y, Ford OH, et al. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. The Prostate 2006 ; 66 : 1292-1301. [CrossRef] [PubMed] [Google Scholar]
- Greiner D, Bonaldi T, Eskeland R, et al. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 2005 ; 1 : 143-145. [CrossRef] [PubMed] [Google Scholar]
- Cook KM, Hilton ST, Mecinovic J, et al. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem 2009 ; 284 : 26831-26838. [CrossRef] [PubMed] [Google Scholar]
- Isham CR, Tibodeau JD, Jin W, et al. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007 ; 109 : 2579-2588. [CrossRef] [PubMed] [Google Scholar]
- Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007 ; 21 : 1050-1063. [CrossRef] [PubMed] [Google Scholar]
- Kubicek S, O’Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007 ; 25 : 473-481. [CrossRef] [PubMed] [Google Scholar]
- Cheng D, Yadav N, King RW, et al. Small molecule regulators of protein arginine methyltransferases. J Biol Chem 2004 ; 279 : 23892-23899. [CrossRef] [PubMed] [Google Scholar]
- Spannhoff A, Machmur R, Heinke R, et al. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett 2007 ; 17 : 4150-4153. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.